New Immune-Boosting drug tested for Tough-to-Treat cancers
NCT ID NCT06882746
Summary
This early-stage study is testing a new drug called BI 765049 in adults with advanced colorectal, stomach, or pancreatic cancer that has spread or cannot be removed by surgery. The main goal is to find the highest dose patients can safely tolerate and determine the best way to give the drug for future studies. Participants receive the drug at least once every three weeks, along with other medications to help manage side effects, for as long as they are benefiting from it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Valkyrie Clinical Trials
RECRUITINGLos Angeles, California, 90067, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.